{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030066","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.000674+00:00","generated_at":"2026-06-22T18:57:17.905561+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Shuttle Pharmaceuticals appoints Dr. Bette Jacobs to Board, fills vacancy","bullets":["Appointed Dr. Bette Jacobs as independent director to fill vacancy left by William Adkins, effective Oct 28, 2022.","Dr. Jacobs will serve on Audit Committee and Nominating and Corporate Governance Committee.","Compensation includes $25,000 annual cash and $100,000 in RSUs vesting over three years.","Board amended bylaws to reduce director term from three years to one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030066","json":"https://secwatch.observer/filing/0001493152-22-030066.json","markdown":"https://secwatch.observer/filing/0001493152-22-030066.md","text":"https://secwatch.observer/filing/0001493152-22-030066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/0001493152-22-030066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T18:57:17.905561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"24a4f2c56c","claim":"William Adkins departed as Director at Shuttle Pharmaceuticals Holdings, Inc..","evidence_excerpt":"seat vacated by William Adkins, an independent director, whose term of service ended effective as of October 28, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/0001493152-22-030066-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"vacated"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"afc23315a6","claim":"Bette Jacobs was appointed as Director at Shuttle Pharmaceuticals Holdings, Inc..","evidence_excerpt":"On October 28, 2022, the board of directors (the “Board”) of Shuttle Pharmaceuticals Holdings, Inc., a Delaware Corporation (the “Company”), based upon the recommendation of the Board’s Nominating and Corporate Governance Committee, approved the appointment of Bette Jacobs, Ph.D. to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315222030066/0001493152-22-030066-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}